ZOMDF (Zomedica) Total Receivables: $4.80 Mil (As of Mar. 2026)


What is Zomedica Total Receivables?

Zomedica ZOMDF +5.58% Total Receivables is $4.80 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Zomedica's Total Receivables for the quarter that ended in Mar. 2026 was $4.80 Mil.

Zomedica Total Receivables Historical Data

* Premium members only.

The historical data trend for Zomedica's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zomedica Total Receivables Chart

Zomedica Annual Data
Trend Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.77 1.86 2.20 3.07 3.46

Zomedica Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.12 2.92 3.63 3.46 4.80

Zomedica Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $4.80 Mil mean?
Zomedica (ZOMDF) has a Total Receivables of $4.80 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Zomedica and its competitors.
Is Zomedica's Total Receivables too high?
Zomedica's current Total Receivables is $4.80 Mil.
How does Zomedica's Total Receivables compare to STIM and OM?
Zomedica's Total Receivables of $4.80 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Zomedica and its competitors. Zomedica's current Total Receivables is $4.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zomedica stock overvalued right now?
Based on GuruFocus' analysis, Zomedica (ZOMDF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.19, compared to a current price of $0.10 — trading 46.8% below its estimated fair value. The current Total Receivables is $4.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Zomedica (ZOMDF), the current Total Receivables is $4.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zomedica Business Description

Address 1101 Technology Drive, Suite 100, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.